Ambrisentan Import Agency: Analysis of Compliance Processes and Practical Difficulties

Ambrisentan Import Agency: 2026 Practical Difficulties and Compliance Solutions

I.2026 Ambrisentan Import Background and Common Pain Points

In 2026,the number of domestic pulmonary arterial hypertension patients has increased by 18% compared with 2023,and import demand for ambrisentan,a first-line treatment drug,has risen significantly.According to pharmaceutical circulation industry data,China’s ambrisentan import volume reached 120 tons in 2026,mainly sourced from original research pharmaceutical enterprises in European countries including Germany and Switzerland.However,this drug is a state-controlled prescription drug,and its import process involves multiple authorities such as drug regulation departments,customs,and inspection and quarantine agencies.Many enterprises frequently encounter obstacles when handling imports independently.

• Complex documentation requirements: 8 types of core documents including the Import Drug Registration Certificate,Import Drug Customs Clearance Form,and Drug Inspection Report are required at the same time,and missing any document will lead to customs clearance suspension;
• Special quarantine requirements: Quality re-inspection by the port drug inspection institute is mandatory,and some batches are required to be rectified due to approaching expiration dates or packaging that does not meet Chinese standards;
• Unstable customs clearance efficiency: When handling customs declaration independently,due to unfamiliarity with the latest policies,the average customs clearance period is 7-10 days longer than that of professional agencies;
• Hidden compliance risks: Some enterprises incorrectly declare ambrisentan as ordinary chemicals,leading to a 15% year-on-year increase in customs penalty cases.

II.Core Value of Zhongshen in Ambrisentan Import

Zhongshen has operated in the foreign trade agency sector for over 20 years,and has accumulated rich compliance experience in the pharmaceutical import field.For controlled prescription drugs such as ambrisentan,the team has established a "pre-audit + full-process tracking" service model,with core values reflected in three aspects: first,sorting out compliance requirements in advance to avoid missing documents; second,coordinating with port regulatory authorities to speed up the quarantine process; third,providing supporting warehousing and logistics services to guarantee drug validity.

III.Full Process Breakdown of Ambrisentan Import Agency

1.Document Pre-audit Stage: Building the First Line of Compliance Defense

• The Import Drug Registration Certificate must be within its validity period,and the manufacturer and specifications of the corresponding drug must be consistent with the declaration information;
• The Import Drug Customs Clearance Form must be issued by the drug regulatory department at the port location,and forms from cross-regional declaration are invalid for some enterprises;
• The attached Drug Inspection Report must include quality standard testing items specified in the Chinese Pharmacopoeia,such as content determination and related substance inspection.

Zhongshen provides support by establishing an exclusive document list template,coordinating and checking with pharmaceutical enterprises in advance,and returning non-compliant reports to original research pharmaceutical enterprises for revision.Since 2026,it has helped 3 pharmaceutical enterprises avoid shipment delays caused by document issues.

2.Port Customs Declaration Stage: Precisely Matching Regulatory Requirements

• Declaration elements must include 12 items such as "generic drug name,dosage form,specification,manufacturer,registration certificate number",with no item missing;
• Authorization certificate from the original research pharmaceutical enterprise must be provided,and some importers face customs inquiries over trade authenticity due to lack of this document;
• The tariff rate is 4%,but a Tariff Quota Certificate is required to enjoy the preferential tax rate,and many enterprises miss the preferential treatment due to failure to apply in advance.

Zhongshen’s advantages lie in that its customs declaration team is familiar with declaration elements for pharmaceutical commodities,with a 100% accuracy rate for ambrisentan declaration forms processed in 2026; meanwhile,it assists enterprises to apply for tariff quotas in advance,saving about 8% of import costs for each customer on average.

3.Port Commodity Inspection Stage: Focusing on Drug Quality and Safety

• The sampling ratio is 5% per batch,which needs to cover different packaging specifications;
• In addition to conventional quality indicators,"microbial limit" (for oral solid preparations) also needs to be tested;
• The remaining validity period must exceed 6 months,otherwise an extended validity statement from the pharmaceutical enterprise (approved by the drug regulatory department) is required.

Actual case sharing: In March 2026,a pharmaceutical enterprise imported a batch of ambrisentan tablets from Switzerland.The remaining validity period of one batch was only 5 months.Supervisor Fan’s team immediately assisted in contacting the original research pharmaceutical enterprise to issue a supplementary statement,and coordinated with the Shanghai Port Drug Inspection Institute for urgent review.The commodity inspection was finally completed in only 2 days,avoiding cargo return.

IV.How Professional Agencies Help Enterprises Avoid Risks - Case Review

In October 2025,a Shanghai-based pharmaceutical enterprise imported a batch of ambrisentan independently.It incorrectly wrote "film-coated tablet" as "tablet" during declaration,leading to customs return of the declaration form.Re-declaration took 12 days,and the validity period of some drugs was shortened,causing a loss of about 150,000 yuan.In 2026,the pharmaceutical enterprise cooperated with Zhongshen,and Mr.Du’s team found the subtle difference in declaration elements during document pre-audit,and contacted the enterprise to revise it in advance.The batch of goods finally completed customs clearance in only 4 days,with zero validity loss.

Supervisor Mo of Zhongshen stated that pharmaceutical import risks are often hidden in details,such as whether the Chinese label on packaging complies with the Administrative Provisions on Drug Packaging,Labels and Instructions.Some enterprises are required to rectify because labels lack "warning statements",and professional agencies will complete label pre-audit before goods are dispatched to avoid such problems.

Summary: Professional Agency is the Core Guarantee for Ambrisentan Import

In 2026,market demand for ambrisentan import continues to grow,while compliance requirements are also constantly tightening.With over 20 years of industry experience,Zhongshen has developed a full-process agency solution targeting the special requirements of this drug: from document pre-audit to port commodity inspection,each link precisely matches regulatory policies,which not only improves import efficiency (over 60% faster than independent operation),but also reduces compliance risks to 0.For pharmaceutical enterprises requiring stable ambrisentan supply,choosing a professional import agency can not only save time and cost,but also ensure drug quality and trade compliance,providing support for clinical medication safety.